|
Title
|
Publication Date
|
Price
|
Relevance
|
Chiesi Farmaceutici SpA – Product Pipeline Review
Q2 2011
|
Jul 2011 |
£315 |
100% |
|
Chiesi Farmaceutici S.p.A-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
93% |
|
Wound Treatments in Italy
|
Mar 2009 |
£560 |
85% |
|
Cough, Cold and Allergy (Hay Fever) Remedies in Italy
|
Apr 2011 |
£600 |
82% |
Respiratory Distress Syndrome Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
74% |
Neonatal Respiratory Distress Syndrome Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
71% |
Asthma Global Clinical Trials Review
H2, 2011
|
Dec 2011 |
£630 |
71% |
Cystic Fibrosis Global Clinical Trials Review
Q2, 2011
|
Jun 2011 |
£630 |
70% |
Alzheimer's Disease Global Clinical Trials Review
H2 2011
|
Oct 2011 |
£630 |
70% |
Inflammatory Bowel Disease Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
69% |
Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review
H2, 2011
|
Dec 2011 |
£630 |
67% |
|
Pulmonary Drug Delivery Technologies
|
Apr 2010 |
£2,845 |
66% |
Cystic Fibrosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
65% |
Post Menopausal Osteoporosis - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
63% |
Osteoporosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
62% |
Alzheimer's Disease - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
60% |
Pulmonary Drug Delivery Technologies
A Global Market Perspective
|
Nov 2009 |
£1,895 |
54% |
Mitsubishi Tanabe Pharma
Pipeline, Products, Performance, Potential
|
Jan 2008 |
£595 |
52% |
Asthma - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
50% |
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
49% |
Cystic Fibrosis (CF) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
47% |
Breast Cancer - Pipeline Review
Q3 2011
|
Jul 2011 |
£315 |
41% |
Alzheimer's disease
Technologies, Markets and Companies
|
Jan 2012 |
£2,265 |
38% |
|
Sorin S.p.A. Market Share Analysis
|
Sep 2010 |
£630 |
37% |
